
Knight Therapeutics Inc GUD.TO:
KNIGHT THERAPEUTICS AND SUMITOMO PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENTS TO COMMERCIALIZE SUMITOMO’S CANADIAN PORTFOLIO
KNIGHT THERAPEUTICS INC - DEAL INCLUDES UPFRONT AMOUNT OF C$25.4 MILLION
KNIGHT THERAPEUTICS: MAY PAY FUTURE CONTINGENT PAYMENTS OF UP TO C$15.75 MILLION
KNIGHT THERAPEUTICS INC - EXPECTED TO PAY C$7 MILLION FOR INVENTORY